|
|
Post by Clement on Aug 8, 2023 8:48:27 GMT -5
So what happened last quarter? Share price went down to close at $3.80 on May 9, the day of the call. The call was at 5:00pm. Next day it closed up 15%.up 15% like last quarter ... so far |
|
|
|
Post by dh4mizzou on Aug 8, 2023 9:01:43 GMT -5
I'm just happy that 7 of my 8 traunches are in the green. The only one that is not (yet) is the pre-reverse split traunch and I don't know what I'll do if that one ever goes green.
EDIT: And if we hit $ 6.28 I'm in the green overall. Woo-Hoo !
|
|
|
|
Post by mango on Aug 8, 2023 9:07:39 GMT -5
Hey guys, been quiet lately but have been watching. Earnings was stellar and loving this price action this morning. I expect new coverage soon and updated price targets. I’ll be working on an updated Milestones and Catalysts list soon. If you have anything specific you want included reply to this message!
With that…Hell yeah, let’s do this!
|
|
|
|
Post by dh4mizzou on Aug 8, 2023 9:11:08 GMT -5
Hey Peppy, what happens if we take out the 52 week high?
EDIT: Forgot Peppy is out of pocket for a few days. Any other technical analysts care to take a shot at my question?
|
|
|
|
Post by LongMNKD on Aug 8, 2023 9:21:46 GMT -5
Its nice when your only regret is not having more shares!
|
|
|
|
Post by celo on Aug 8, 2023 9:28:56 GMT -5
5.50 has been a barrier for the last 2 and half years. MNKD has crossed it for a little while and then came back. Now that the analysts can figure out how profitable mannkind will be in the future, time to go way past 6
|
|
|
|
Post by prcgorman2 on Aug 8, 2023 9:50:14 GMT -5
Just once I'd like to see a disorderly exit of the shorts.
|
|
|
|
Post by sr71 on Aug 8, 2023 10:51:55 GMT -5
That could easily happen between now and the 3rd Qtr earnings release in early November, or very shortly thereafter.
|
|
|
|
Post by akemp3000 on Aug 8, 2023 10:56:09 GMT -5
Agree. Regardless of when and how shorts exit, you can take it to the bank that many are either concerned or rethinking their position after this 2Q report.
|
|
|
|
Post by castlerockchris on Aug 8, 2023 10:58:58 GMT -5
Short squeezes are hard to do anything with, by the time you figure out it truly is a short squeeze and not a deserved run up, it is over and the price comes back down to earth. FOMO prevented me from selling during the last squeeze. This time I will hopefully be smarter and at least sell covered calls. I did sell some Nov $8 calls this morning. We shall see where we go from here.
|
|
|
|
Post by BD on Aug 8, 2023 11:09:02 GMT -5
Just once I'd like to see a disorderly exit of the shorts. So would my still-down-30% January 5.5 calls...  |
|
|
|
Post by uvula on Aug 8, 2023 11:26:09 GMT -5
10M shares traded already today.
|
|
|
|
Post by cjc04 on Aug 8, 2023 11:28:38 GMT -5
So what happened last quarter? Share price went down to close at $3.80 on May 9, the day of the call. The call was at 5:00pm. Next day it closed up 15%.up 15% like last quarter ... so far one “little” difference is 6.37m shares traded on 5/10… today, at just past noon, we’re over 10m traded. Hoping that means something more substantial is happening today. |
|
|
|
Post by awesomo on Aug 8, 2023 12:11:25 GMT -5
Just once I'd like to see a disorderly exit of the shorts. We did, when Afrezza surprisingly got FDA approval. Or maybe even when we got pumped and dumped to $6 back in 2017. Neither went too well afterwards though. I'll take these good earnings calls and a steady decline in short interest over that. |
|
|
|
Post by prcgorman2 on Aug 8, 2023 12:46:18 GMT -5
Just once I'd like to see a disorderly exit of the shorts. We did, when Afrezza surprisingly got FDA approval. Or maybe even when we got pumped and dumped to $6 back in 2017. Neither went too well afterwards though. I'll take these good earnings calls and a steady decline in short interest over that. SHORTly after Afrezza got FDA approval due to a unanimous recommendation of an Advisory Committee, MannKind inked a $1B+ worldwide marketing agreement. Yes, Sanofi fired their CEO and hired Oliver Brandicoot who was the lead executive that presided over the Pfizer disaster known as Exubera RAA and the "bong" which led immediately to a predictable jettison of MNKD from the Sanofi portfolio.
I would say that not only did the shorts not exit, they thrived which is how MNKD ended up on the SEC's SHO list of companies suffering from predatory naked shorting. That's such a great list. It's the SEC telling investors, "Hey, if I were you, I'd stay away from these stocks because the shorts are trying to kill them". A nice way to pile on to what the shorts started with "catch and kill".
If some shorts got burned by the 2017 price action, that would be lamentable, if you're a short.
I noticed the FINRA data for yesterday indicated more than 60% of the FINRA-reported volume (which is typically half what NASDAQ reports) was shares sold short. I'm betting today's percentage will be similar or higher.
Just once, I'd like to see an exceedingly disorderly exit of the shorts.
|
|
